Veracyte (VCYT) CEO sells 138K shares after stock option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Veracyte, Inc. chief executive Marc Stapley reported an exercise-and-sale transaction in company stock. On June 4, 2026 he exercised stock options covering 138,051 shares of common stock at $36.60 per share and sold the same 138,051 shares in open-market trades at a weighted average price of $50.1234 per share pursuant to a Rule 10b5-1 plan.
The filing shows 9,012 shares of common stock were withheld on June 2, 2026 to cover tax obligations tied to vesting restricted stock units, which the company notes does not represent a sale. Following these transactions, Stapley directly owns 440,494 shares of Veracyte common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 138,051 shares ($6,919,585)
Net Sell
4 txns
Insider
Stapley Marc
Role
Chief Executive Officer
Sold
138,051 shs ($6.92M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 138,051 | $0.00 | -- |
| Exercise | Common Stock | 138,051 | $36.60 | $5.05M |
| Sale | Common Stock | 138,051 | $50.1234 | $6.92M |
| Tax Withholding | Common Stock | 9,012 | $47.80 | $431K |
Holdings After Transaction:
Stock Option (right to buy) — 0 shares (Direct, null);
Common Stock — 578,545 shares (Direct, null)
Footnotes (1)
- Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale. Due to an administrative error, shares of common stock acquired by the Reporting Person under the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2025 were incorrectly reported as 529 shares of common stock instead of 382 shares of common stock in a Form 4 filed on September 4, 2025, and these shares were overreported in subsequent Forms 4 filed by the Reporting Person. This column reflects the corrected balance. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025. Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.52. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. The option is fully vested.
Key Figures
Shares sold: 138,051 shares
Weighted average sale price: $50.1234 per share
Option exercise price: $36.60 per share
+3 more
6 metrics
Shares sold
138,051 shares
Open-market sale of common stock on June 4, 2026
Weighted average sale price
$50.1234 per share
Common stock sold on June 4, 2026
Option exercise price
$36.60 per share
Stock options exercised for 138,051 shares
Shares withheld for taxes
9,012 shares
Tax withholding on RSU vesting June 2, 2026
Shares owned after transactions
440,494 shares
Direct Veracyte common stock holdings post-transaction
Option expiration date
June 1, 2031
Original expiration for exercised stock option grant
Key Terms
Rule 10b5-1 plan, restricted stock units, weighted average sales price, Employee Stock Purchase Plan, +1 more
5 terms
Rule 10b5-1 plan regulatory
"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock units financial
"withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sales price financial
"Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.52."
Employee Stock Purchase Plan financial
"shares of common stock acquired by the Reporting Person under the Veracyte, Inc. Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
tax withholding obligations financial
"withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting"
FAQ
What insider transactions did Veracyte (VCYT) CEO Marc Stapley report?
Marc Stapley reported exercising options for 138,051 Veracyte shares at $36.60 and selling the same 138,051 shares in open-market trades at a weighted average price of $50.1234 per share, all under a pre-arranged Rule 10b5-1 trading plan.
Was Marc Stapley’s Veracyte (VCYT) stock sale pre-planned under Rule 10b5-1?
Yes. The Form 4 states the transactions were made under a Rule 10b5-1 plan adopted by Marc Stapley on November 24, 2025. Such plans pre-schedule trades, indicating the sale timing was arranged in advance rather than decided opportunistically.